Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Podsadecki TJ"'
1
Akademický článek
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 2 viremia.
Autor: Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ
Publikováno v: Journal of Infectious Diseases; 12/15/2007, Vol. 196 Issue 12, p1773-1778, 6p
Zobrazit plný text záznamu
2
Akademický článek
Journal pricing issues: an economic perspective.
Autor: Hafner AW (AUTHOR), Podsadecki TJ (AUTHOR), Whitely WP (AUTHOR)
Publikováno v: Bulletin of the Medical Library Association. 1990 Jul, Vol. 78 Issue 3, p217-223. 7p.
Zobrazit plný text záznamu
3
Akademický článek
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1.
Autor: Maroldo, L, Fredrick, LM, Robinson-Morgan, K, Trinh, R, Podsadecki, TJ
Publikováno v: Journal of the International AIDS Society; Nov2010 Supplement S3, Vol. 13, pP30-P30, 2p
Zobrazit plný text záznamu
4
Akademický článek
Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection.
Autor: Polepally AR; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA., Wang H; Biometrics, AbbVie Inc, North Chicago, Illinois, USA., Marroum PJ; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA., Minocha M; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA., Hosmane B; Biometrics, AbbVie Inc, North Chicago, Illinois, USA., Khatri A; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA., Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co, Ludwigshafen am Rhein, Germany., Podsadecki TJ; Infectious Disease Development, AbbVie Inc, North Chicago, Illinois, USA., Cohen DE; Infectious Disease Development, AbbVie Inc, North Chicago, Illinois, USA., Awni WM; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA., Menon RM; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc, North Chicago, Illinois, USA. rajeev.menon@abbvie.com.
Publikováno v: The AAPS journal [AAPS J] 2017 Sep; Vol. 19 (5), pp. 1523-1535. Date of Electronic Publication: 2017 Jul 06.
Zobrazit plný text záznamu
5
Akademický článek
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Autor: Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co., KG, Knollstrasse 50, 67061, Ludwigshafen am Rhein, Germany., Eckert D; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co., KG, Knollstrasse 50, 67061, Ludwigshafen am Rhein, Germany., Sharma S; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.; Department of Clinical Pharmacology, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA, 94404, USA., Polepally AR; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA., Khatri A; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA., Podsadecki TJ; Virology, R48U, AP-30, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA., Awni WM; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA., Menon RM; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA., Dutta S; Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2017 Mar; Vol. 83 (3), pp. 527-539. Date of Electronic Publication: 2016 Nov 03.
Zobrazit plný text záznamu
6
Akademický článek
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Autor: Polepally AR; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA. akshanth.r.polepally@abbvie.com., King JR; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Ding B; Biometrics, AbbVie Inc., Dept. R43V, Bldg. AP31-2, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Shuster DL; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Dumas EO; Infectious Disease Development, AbbVie Inc., Dept. R48U, Bldg. AP30-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Khatri A; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Chiu YL; Biometrics, AbbVie Inc., Dept. R43V, Bldg. AP31-2, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Podsadecki TJ; Infectious Disease Development, AbbVie Inc., Dept. R48U, Bldg. AP30-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA., Menon RM; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie Inc., Dept. R4PK, Bldg. AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064, USA.
Publikováno v: Clinical pharmacokinetics [Clin Pharmacokinet] 2016 Aug; Vol. 55 (8), pp. 1003-14.
Zobrazit plný text záznamu
7
Akademický článek
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Autor: Polepally AR; AbbVie Inc, North Chicago, IL, USA., Dutta S; AbbVie Inc, North Chicago, IL, USA., Hu B; AbbVie Inc, North Chicago, IL, USA., Podsadecki TJ; AbbVie Inc, North Chicago, IL, USA., Awni WM; AbbVie Inc, North Chicago, IL, USA., Menon RM; AbbVie Inc, North Chicago, IL, USA.
Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2016 Jul; Vol. 5 (4), pp. 269-77. Date of Electronic Publication: 2016 Jan 24.
Zobrazit plný text záznamu
8
Akademický článek
Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
Autor: Menon RM; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie, 1 North Waukegan Road, AP31-3, North Chicago, Illinois, 60064., Klein CE; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie, 1 North Waukegan Road, AP31-3, North Chicago, Illinois, 60064., Podsadecki TJ; Infectious Diseases, R48U, AP-30, AbbVie, 1 North Waukegan Road, North Chicago, Illinois, 60064., Chiu YL; Department of Biometrics, AbbVie, 1 North Waukegan Road, AP31-2, North Chicago, Illinois, 60064., Dutta S; Clinical Pharmacokinetics and Pharmacodynamics, AbbVie, 1 North Waukegan Road, AP31-3, North Chicago, Illinois, 60064., Awni WM; Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, R4PD AP31-3, North Chicago, IL, 60064, USA.
Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2016 May; Vol. 81 (5), pp. 929-40. Date of Electronic Publication: 2016 Feb 24.
Zobrazit plný text záznamu
9
Akademický článek
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.
Autor: Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67065, Ludwigshafen am Rhein, Germany. sven.mensing@abbvie.com., Polepally AR; AbbVie Inc., North Chicago, Illinois, USA., König D; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67065, Ludwigshafen am Rhein, Germany., Khatri A; AbbVie Inc., North Chicago, Illinois, USA., Liu W; AbbVie Inc., North Chicago, Illinois, USA., Podsadecki TJ; AbbVie Inc., North Chicago, Illinois, USA., Awni WM; AbbVie Inc., North Chicago, Illinois, USA., Menon RM; AbbVie Inc., North Chicago, Illinois, USA., Dutta S; AbbVie Inc., North Chicago, Illinois, USA.
Publikováno v: The AAPS journal [AAPS J] 2016 Jan; Vol. 18 (1), pp. 270-80. Date of Electronic Publication: 2015 Nov 23.
Zobrazit plný text záznamu
10
Akademický článek
Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
Autor: Polepally AR; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Badri PS; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Parikh A; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Rodrigues L Jr; Infectious Disease Development, AbbVie Inc., North Chicago, IL, USA., Da Silva-Tillmann BA; Global Pharmacovigilance, AbbVie Inc., North Chicago, IL, USA., Mensing S; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Podsadecki TJ; Infectious Disease Development, AbbVie Inc., North Chicago, IL, USA., Awni WM; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Dutta S; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA., Menon RM; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA.
Publikováno v: Antiviral therapy [Antivir Ther] 2016; Vol. 21 (8), pp. 707-714. Date of Electronic Publication: 2016 Sep 01.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje